|
U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH NIH News National Institute on Drug Abuse (NIDA)<https://www.drugabuse.gov/> For Immediate Release: Wednesday, May 8, 2024 CONTACT: NIDA Press Office, <e-mail:media@xxxxxxxxxxxx>,301-443-6245 FASTER APPROACH FOR STARTING EXTENDED-RELEASE NALTREXONE TO TREAT OPIOID USE DISORDER SHOWN EFFECTIVE NIH-supported clinical trial addresses important barrier to opioid use disorder treatment
Starting people with opioid use disorder on extended-release, injectable naltrexone (XR-naltrexone) within five to seven days of seeking treatment is more effective than the standard treatment method of starting within 10-15 days, but requires
closer medical supervision, according to results from a clinical trial <http://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2024.9744?utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_term=050824> supported
by the National Institutes of Health’s (NIH) National Institute on Drug Abuse (NIDA). Published in JAMA Network Open, the findings suggest that this rapid treatment protocol could make XR-naltrexone more viable as a treatment option for opioid use disorder,
which continues to take lives at an alarming rate. “When someone is ready to seek treatment for opioid use disorder, it is crucial that they receive it as quickly as possible,” said Nora Volkow, M.D., NIDA director. “This study paves the way for more timely care with one of the three medications
for opioid use disorder we have available, better supporting people in their ability to choose the treatment option that will work best for them.”
XR-naltrexone<https://www.samhsa.gov/medications-substance-use-disorders/medications-counseling-related-conditions/naltrexone> is one of three Food and Drug Administration-approved medications for the treatment of opioid use disorder<https://nida.nih.gov/research-topics/opioids/medications-opioid-overdose-withdrawal-addiction-infographic>.
It works by binding to and blocking opioid receptors in the brain, which reduces opioid cravings and prevents the euphoric and sedative effects of opioids. However, starting treatment with XR-naltrexone has traditionally required patients to go through a seven
to 10-day opioid-free period, to avoid experiencing painful withdrawal symptoms caused when naltrexone abruptly stops the effects of opioids in the brain. During this waiting period, patients are at high risk of returning to opioid use or discontinuing treatment.
This has been a significant barrier to implementation of XR-naltrexone. To address this challenge, researchers tested the effectiveness of a more rapid procedure to start people with opioid use disorder on XR-naltrexone. Between March 2021 and September 2022, the study enrolled and followed 415 patients with
opioid use disorder who were admitted at six community-based inpatient addiction facilities across the U.S. and who chose treatment with XR-naltrexone. Every 14 weeks, the sites were randomized to either provide the standard XR-naltrexone procedure, or the
more rapid procedure. In the study, standard XR-naltrexone prescribing included a three- to five-day treatment period with buprenorphine to ease withdrawal symptoms, followed by a seven- to 10-day opioid-free period. The rapid procedure consisted of one day
of buprenorphine (up to 10 mg), a 24-hour opioid-free period, and a gradual increase in low-dose oral naltrexone for three to four days prior to getting an injection of XR-naltrexone. Doctors also used medications such as clonidine and clonazepam throughout
the process to manage withdrawal symptoms. The study found that patients on the rapid five to seven-day treatment procedure were significantly more likely to receive a first injection of XR-naltrexone compared to those on the standard seven to 15-day treatment procedure (62.7% vs.
35.8%). Withdrawal severity was generally low and comparable across the two groups. Targeted safety events and serious adverse events (such as a fall or overdose) were infrequent overall but occurred more on rapid procedure (5.3% and 6.7%) than on standard
procedure (2.1% and 1.6%), and the rapid procedure required more staff attention. This indicates that closer monitoring and greater clinical expertise may be needed if patients start treatment with the rapid procedure. Though the shorter wait-time improved the proportion of people who started on XR-naltrexone overall, these findings underscore that challenges remain in starting patients on XR-naltrexone and also keeping them in treatment long term. Across
both the standard and rapid procedures, the most commonly reported reason that participants did not receive a first dose of XR-naltrexone was that they chose to leave the treatment unit early. The authors also note that only about 10% of all patients entering
treatment chose XR-naltrexone. These findings reaffirm that a small but sizable proportion of people with opioid use disorder do opt for treatment with XR-naltrexone when presented with all three medication choices, and that it is important to support research
into making this evidence-based treatment option more viable for those who choose it.
“Time has been an important barrier that we’ve seen hinder the use of extended-release naltrexone for opioid use disorder in the past, both among individuals and treatment providers,” said Matisyahu Shulman, M.D., a clinician researcher
at New York State Psychiatric Institute and Columbia University Irving Medical Center, New York City, and lead author on the study. “We hope that these findings can help encourage more treatment settings to offer extended-release naltrexone as a safe and effective
option for patients, to help prevent overdose and support recovery.” The authors note that future studies should explore sustainability, feasibility, and health economic aspects of this more rapid treatment protocol for XR-naltrexone. Despite cost savings from fewer days on the rapid procedure, the resources
needed for intensive monitoring should also be considered. In 2022, over 107,000 people died of a drug overdose, with 75% of those deaths involving an opioid. The overall rise in overdose deaths is largely attributable to the proliferation in the drug supply of illicit fentanyl, a highly potent
synthetic opioid. Decades of research have shown the overwhelming benefit of three existing medications for opioid use disorder: methadone, buprenorphine, and XR-naltrexone.
The study, known as the Surmounting Withdrawal to Initiate Fast Treatment with Naltrexone (SWIFT) study<https://www.clinicaltrials.gov/study/NCT04762537>, was conducted at six sites within the NIDA Clinical Trials Network <https://nida.nih.gov/organization/center-clinical-trials-network-cctn/clinical-trials-network-ctn>
and funded through NIH’s Helping to End Addiction Long-Term Initiative (or NIH HEAL initiative)<https://heal.nih.gov/>. The study was led by researchers at New York State Psychiatric Institute and Columbia University Irving Medical Center.
If you or someone you know is struggling or in crisis, help is available. Call or text 988 or chat at 988lifeline.org. To learn how to get support for mental health, drug or alcohol issues, visit FindSupport.gov. If you are ready to locate
a treatment facility or provider, you can go directly to FindTreatment.gov or call 800-662-HELP (4357).
About the National Institute on Drug Abuse (NIDA): NIDA is a component of the National Institutes of Health, U.S. Department of Health and Human Services. NIDA supports most of the world’s research on the health aspects of drug use and
addiction. The Institute carries out a large variety of programs to inform policy, improve practice, and advance addiction science. For more information about NIDA and its programs, visit www.nida.nih.gov. About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting
and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit <https://www.nih.gov>. NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office --- REFERENCE: M Shulman, et al. Rapid Initiation of Injection Naltrexone for Opioid Use Disorder: A Stepped-wedge, Cluster-Randomized Clinical Trial. JAMA Network Open. DOI: 10.1001/jamanetworkopen.2024.9744 (2024). ### <https://www.nih.gov/news-events/news-releases/faster-approach-starting-extended-release-naltrexone-treat-opioid-use-disorder-shown-effective> <http://service.govdelivery.com/service/subscribe.html?code=USNIH_1>. If you subscribed via the NIH LISTSERV, go to <https://list.nih.gov/cgi-bin/wa.exe?A0=nihpress>. |
